MetLife Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? MetLife Inc. Common Stock trades at $102.41 (market cap $63.96B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: MetLife Inc. Common Stock is far larger — about 35.5× Vir Biotechnology Inc. Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.35% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MetLife Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| MET | VIR | |
|---|---|---|
Market Cap | $63.96B | $1.80B |
Volume | 3,016,459 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $100.65 | $11.78 |
52-Week Low | $67.70 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $84.89B | $1.36B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
MetLife (MET) trades at $100.65, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with a P/E of 19.28 and a net income margin of 4.66%. Recent news highlights a declared dividend of $0.59 per share and upcoming Q3 2026 results.
The outlook for MET is positive, driven by earnings momentum and a favorable interest rate environment for insurers. Key risks include investment income volatility and competitive pressures. With a consensus price target of $108.25 and no sell ratings, Wall Street sentiment remains bullish, though the stock's RSI suggests potential near-term overbought conditions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →